Patents Assigned to HSC Research and Development Limited Partnership
  • Patent number: 8058243
    Abstract: A clonogenic neurosphere assay is described that carries out high throughput screens (HTS) to identify potent and/or selective modulators of proliferation, differentiation and/or renewal of neural precursor cells, neural progenitor cells and/or self-renewing and multipotent neural stem cells (NSCs). Compositions comprising the identified modulators and methods of using the modulators and compositions, in particular to treat neurological disorders (e.g. brain or CNS cancer) or damage are also disclosed.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: November 15, 2011
    Assignees: HSC Research and Development Limited Partnership, Mount Sinai Hospital
    Inventors: Mike Tyers, Phedias Diamandis, Peter B. Dirks
  • Patent number: 7846679
    Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.
    Type: Grant
    Filed: October 28, 2008
    Date of Patent: December 7, 2010
    Assignees: HSC Research and Development Limited Partnership, The Governing Council of the University of Toronto
    Inventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
  • Patent number: 7838247
    Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: November 23, 2010
    Assignees: HSC Research and Development Limited Partnership, The Governing Council of the University of Toronto
    Inventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
  • Patent number: 7598419
    Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed.
    Type: Grant
    Filed: March 22, 2005
    Date of Patent: October 6, 2009
    Assignee: HSC Research and Development Limited Partnership
    Inventors: Chaim M. Roifman, Peter Demin, Andrew Freywald, Thomas Grunberger, Olga Rounova, Nigel Sharfe
  • Publication number: 20090191650
    Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.
    Type: Application
    Filed: October 28, 2008
    Publication date: July 30, 2009
    Applicants: The Governing Council of the University of Toronto, HSC Research and Development Limited Partnership
    Inventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
  • Patent number: 7560426
    Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.
    Type: Grant
    Filed: March 12, 2007
    Date of Patent: July 14, 2009
    Assignees: HSC Research and Development Limited Partnership, Ontario Cancer Institute
    Inventors: Clifford A. Lingwood, Ruth Geva, legal representative, Leorah Kroyanker, legal representative, Richard Hill, Hannah Farkas-Himsley
  • Patent number: 7507798
    Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: March 24, 2009
    Assignees: HSC Research and Development Limited Partnership, The Governing Council of the University of Toronto
    Inventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
  • Publication number: 20090076019
    Abstract: A clonogenic neurosphere assay is described that carries out high throughput screens (HTS) to identify potent and/or selective modulators of proliferation, differentiation and/or renewal of neural precursor cells, neural progenitor cells and/or self-renewing and multipotent neural stem cells (NSCs). Compositions comprising the identified modulators and methods of using the modulators and compositions, in particular to treat neurological disorders (e.g. brain or CNS cancer) or damage are also disclosed.
    Type: Application
    Filed: October 12, 2007
    Publication date: March 19, 2009
    Applicants: Mount Sinai Hospital, HSC Research and Development Limited Partnership
    Inventors: Mike Tyers, Phedias Diamandis, Peter B. Dirks
  • Publication number: 20070243612
    Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed.
    Type: Application
    Filed: March 22, 2005
    Publication date: October 18, 2007
    Applicant: HSC Research and Development Limited Partnership
    Inventors: Chaim Roifman, Peter Demin, Andrew Freywald, Thomas Grunberger, Olga Rounova, Nigel Sharfe
  • Patent number: 7208468
    Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: April 24, 2007
    Assignees: HSC Research and Development Limited Partnership, Ontario Cancer Institute
    Inventors: Clifford A. Lingwood, Ruth Geva, legal representative, Leorah Kroyanker, legal representative, Richard Hill, Hannah Farkas-Himsley, deceased
  • Patent number: 7118886
    Abstract: The present invention describes the identification, isolation and characterization of novel mammalian proteins encoded by the Ese1 and Ese2 genes which are involved in endocytosis, vesicular trafficking and regulation of the actin cytoskeleton. Transcripts and products of these genes are useful for detecting abnormal cellular endocytosis processes as well as for developing assay systems to find and elucidate further binding partners of the proteins, to develop therapeutics to alter/restore protein function and for the isolation and manufacture of Ese proteins.
    Type: Grant
    Filed: April 27, 1999
    Date of Patent: October 10, 2006
    Assignee: HSC Research and Development Limited Partnership
    Inventors: Sean E. Egan, Wei Wang, Ameet Sengar
  • Patent number: 7105636
    Abstract: A new family of proteins, the SARA proteins, has been identified. These proteins bind to receptor-regulated Smad proteins and modulate signal transduction by TGF?, activin and bone morphogenetic protein.
    Type: Grant
    Filed: July 20, 1999
    Date of Patent: September 12, 2006
    Assignee: HSC Research and Development Limited Partnership
    Inventor: Jeffrey L. Wrana
  • Patent number: 6998467
    Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: February 14, 2006
    Assignees: The Hospital for Sick Children, HSC Research and Development Limited Partnership, The Governing Council of the University of Toronto
    Inventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
  • Patent number: 6835710
    Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.
    Type: Grant
    Filed: August 3, 2000
    Date of Patent: December 28, 2004
    Assignees: HSC Research & Development Limited Partnership, Ontario Cancer Institute
    Inventors: Clifford A. Lingwood, Hannah Farkas-Himsley, Richard Hill
  • Publication number: 20040209845
    Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed.
    Type: Application
    Filed: March 17, 2004
    Publication date: October 21, 2004
    Applicant: HSC Research and Development Limited Partnership
    Inventors: Chaim M. Roifman, Thomas Grunberger, Olga Rounova, Demin Peter, Nigel Sharfe
  • Patent number: 6800659
    Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: October 5, 2004
    Assignee: HSC Research and Development Limited Partnership
    Inventors: Chaim M. Roifman, Thomas Grunberger, Olga Rounova, Demin Peter, Nigel Sharfe
  • Patent number: 6765086
    Abstract: A polypeptide is provided that has a secondary structure characterized by at least three beta-sheet/beta-turn structures, and that is not a naturally occurring fibrous protein. Such polypeptides, illustrated by one modeled on elastin, are useful in prosthesis.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: July 20, 2004
    Assignees: Protein Specialties, Ltd., HSC Research & Development Limited Partnership
    Inventors: Aser Rothstein, Fred Keeley, Steven Rothstein
  • Patent number: 6696272
    Abstract: The invention relates to products and methods for medical treatment of Gaucher disease and, in particular, an improved Gcc DNA for insertion into any applicable expression vector for gene therapy treatment. The invention includes an isolated Gcc DNA molecule, wherein nucleic acid molecules have been modified at cryptic splice sites to prevent or decrease splicing of mRNA produced from the DNA molecule, while preserving the ability of the DNA to express functional Gcc polypeptides.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: February 24, 2004
    Assignee: HSC Research & Development Limited Partnership
    Inventors: Don J. Mahuran, Joe T. R. Clarke, John W. Callahan
  • Publication number: 20040006777
    Abstract: The invention provides a human gene encoding two new cytoplasmic phosphatases, Lyp1 and Lyp2, as well as the proteins and methods for preparing and using the described gene and proteins.
    Type: Application
    Filed: December 3, 2002
    Publication date: January 8, 2004
    Applicant: HSC Research and Development Limited Partnership
    Inventor: Chaim M. Roifman
  • Patent number: 6562957
    Abstract: A method of diagnosing hereditary haemorrhagic telangiectasia (HHT) which includes the steps of: obtaining a sample of genomic DNA from a patient or fetus; and determining whether the DNA contains a mutation in a gene encoding endoglin, betaglycan, TGF-&bgr; type I receptor (RI), TGF-&bgr; type II receptor (RII), or TGF-&bgr;/activin type I receptor (TSR-I), such a mutation being an indication that the patient or fetus bears a gene making the patient or fetus susceptible to HHT.
    Type: Grant
    Filed: September 28, 1999
    Date of Patent: May 13, 2003
    Assignees: HSC Research & Development Limited Partnership, Duke University
    Inventors: Michelle Letarte, Douglas A. Marchuk, Kimberly McAllister